Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Only a handful of stem cell therapies are currently approved by the F.D.A., mainly for treating blood cancer and immune ...

Our immune system is designed to protect us by recognizing and attacking infected or abnormal cells. However, cancer cells ...

Adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) face significant survival disparities and ...